Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. Geron stock is seeing huge sell-offs on the heels of ...

Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron (NASDAQ:GERN) stock plunged 30% after management reportedly indicated on the company's Q4 earnings call that sales of ...

Wedbush is removing Geron (GERN) from the firm’s Best Ideas List due to its investment price discipline. Wedbush has an Outperform rating on ...

Fintel reports that on February 26, 2025, HC Wainwright & Co. downgraded their outlook for Geron (NasdaqGS:GERN) from Buy to ...

Geron (GERN) delivered earnings and revenue surprises of -100% and 4.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Barclays analyst Peter Lawson lowered the firm’s price target on Geron (GERN) to $4 from $9 and keeps an Overweight rating on the shares post ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...